CGEM vs. SRRK, BCRX, AUTL, XNCR, IMTX, PROK, FDMT, VIR, RLAY, and TARS
Should you be buying Cullinan Oncology stock or one of its competitors? The main competitors of Cullinan Oncology include Scholar Rock (SRRK), BioCryst Pharmaceuticals (BCRX), Autolus Therapeutics (AUTL), Xencor (XNCR), Immatics (IMTX), ProKidney (PROK), 4D Molecular Therapeutics (FDMT), Vir Biotechnology (VIR), Relay Therapeutics (RLAY), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "medical" sector.
Cullinan Oncology (NASDAQ:CGEM) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.
Cullinan Oncology has higher earnings, but lower revenue than Scholar Rock. Cullinan Oncology is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.
86.3% of Cullinan Oncology shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 8.8% of Cullinan Oncology shares are held by company insiders. Comparatively, 26.2% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Cullinan Oncology's return on equity of -27.92% beat Scholar Rock's return on equity.
Scholar Rock received 114 more outperform votes than Cullinan Oncology when rated by MarketBeat users. However, 79.07% of users gave Cullinan Oncology an outperform vote while only 63.25% of users gave Scholar Rock an outperform vote.
In the previous week, Cullinan Oncology had 4 more articles in the media than Scholar Rock. MarketBeat recorded 15 mentions for Cullinan Oncology and 11 mentions for Scholar Rock. Cullinan Oncology's average media sentiment score of 0.74 beat Scholar Rock's score of -0.07 indicating that Cullinan Oncology is being referred to more favorably in the media.
Cullinan Oncology presently has a consensus price target of $32.00, indicating a potential upside of 34.40%. Scholar Rock has a consensus price target of $25.17, indicating a potential upside of 75.74%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Cullinan Oncology.
Cullinan Oncology has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.
Summary
Scholar Rock beats Cullinan Oncology on 10 of the 18 factors compared between the two stocks.
Get Cullinan Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cullinan Oncology Competitors List
Related Companies and Tools
